In this project, 10 partner institutions (3 research institutions and 7 companies) will work together to prepare for, commence and complete initial clinical development of PRS-080, a novel Anticalin therapeutic for the treatment of anemia of chronic disease (ACD).
All partners have outstanding research and development capabilities in their respective field. Their expertise – as demonstrated by numerous publications and patent applications – will contribute to the success of the project.
Please click on the partners’ names for a brief description of each organization, the contribution each will make to the EUROCALIN project and contact information.
All partners have outstanding research and development capabilities in their respective field. Their expertise – as demonstrated by numerous publications and patent applications – will contribute to the success of the project.
Please click on the partners’ names for a brief description of each organization, the contribution each will make to the EUROCALIN project and contact information.
Partners